IMMA Health, an Israeli health-tech company developing groundbreaking at-home reproductive care technology, has secured a $1.6 million grant from the Israel Innovation Authority while simultaneously earning the prestigious Seal of Excellence from the European Innovation Council (EIC).
The company is pioneering the world's first self-operated transvaginal ultrasound solution—a platform that combines robotics with artificial intelligence to enable women to perform 3D pelvic ultrasound scans independently from their homes. The technology promises to democratize access to reproductive healthcare while providing physicians with standardized, automated reports that could significantly improve clinical decision-making.
Addressing critical gaps in women's health
The innovation targets a fundamental challenge in women's healthcare: limited access to reproductive and fertility care. IMMA's device is initially designed to streamline fertility monitoring processes and potentially increase success rates for In Vitro Fertilization (IVF) treatments, which could benefit millions of women worldwide seeking fertility assistance.
"This dual recognition, from both the vibrant Israeli ecosystem and the leading European body, is a pivotal milestone for us," said Beatrice Chemla, CEO and co-founder of IMMA Health. "It validates our vision to give women control and clarity over their own bodies, while providing physicians and healthcare providers with automated reports and standardized, comparable ultrasound imaging."
International recognition and market potential
The EIC's Seal of Excellence is awarded only to select deep-tech companies whose proposals demonstrate exceptional potential for European and global impact. The international panel of experts praised IMMA's development as having "game-changing character in the field of IVF treatments" and representing "a breakthrough in ultrasound diagnostics."
The evaluators noted that the project addresses critical global trends, including declining fertility rates and the healthcare industry's shift toward remote medicine solutions. They emphasized the venture's "significant potential to transform the existing market thanks to its clear added value for both clinics and patients."
Beyond fertility: broader health applications
While initially focused on fertility treatments, IMMA's technology has broader implications for women's health. The company believes its platform could eventually help identify conditions such as endometriosis, Polycystic Ovary Syndrome (PCOS), and certain cancers through earlier, less invasive detection methods.
"Our technology doesn't just improve fertility treatments; it has the potential to disrupt the fertility market by tripling accessibility at a more affordable cost," Chemla explained. The company estimates its solution could provide more affordable, accessible, and private care compared to traditional clinical settings.
Next steps and market entry
IMMA Health is currently completing its seed funding round, with plans to use the financing to accelerate development, conduct clinical trials, and prepare for regulatory approvals in both the United States and Europe. The company aims to bring its breakthrough technology to market as it works toward FDA approval and other international regulatory clearances.
The dual recognition from Israeli and European innovation authorities positions IMMA at the forefront of the women's health technology revolution, potentially transforming how reproductive healthcare is delivered globally.